Selling 70,000,000 shares to Lincoln Park Capital at .05/share will give Gerald the $3,500,000 needed for the ESS deal.
More shares will have to be sold to raise operating capital.
Gerald has enough shares to fund the company over the next twelve months. I expect he'll use all of the additional one billion shares over the next 12-14 months.
Six months from now when Lympro revenue start rolling we will all forget about SS. Lympro is in position to control market share in Alzheimer's blood test. With US market 1 billion and 3 billion global market for Lympro Sales with absolute no competition.
If Gerald says there is no R/S, then it makes sense why he is saying so.
Why AMBS is commercializing Lympro and planning for spinoff when they have no business doing being holding company. Lympro is already developed why not sell to pharma company.It is because they know the potential of Lympro and they know they can make billions of dollars year in year out than selling to big pharma for few hundred millions.
News 
Market Data 
Discover 
AI
